Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · OCULAR THERAPEUTIX, INC (OCUL)

Ocular Therapeutix Chief Strategy Officer Sanjay Nayak resigns effective October 16, 2026

Neutral Impact 2 of 5 leadership Written later

Ocular Therapeutix said its Chief Strategy Officer, Sanjay Nayak, resigned, effective October 16, 2026, to become CEO of a privately held company. The filing does not name a successor or describe any transition arrangements.

Key points

  • Sanjay Nayak notified the company of his resignation on October 14, 2026.
  • Resignation is effective October 16, 2026.
  • He is leaving to become Chief Executive Officer of a privately held company, which the filing does not name.
  • The filing does not name a successor or give financial terms.

The filing

CompanyOCULAR THERAPEUTIX, INC (OCUL)
Form8-K, current report
Filed with the SECOct 16, 2026, 4:15 PM ET
Accession number0001104659-26-116617

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.